Summary
Torsade de pointes is a polymorphic ventricular tachycardia showing a peculiar electrocardiographic pattern characterised by a continuous twisting in QRS axis around an imaginary baseline.
An abnormally prolonged QT interval is actually associated with torsade de pointes and it is constantly observed in the sinus beats preceding the onset of the arrhythmic event. Prolongation of ventricular repolarisation associated with the development of torsade de pointes can be observed in many clinical conditions, commonly referred to as prolonged QT syndromes, which can be divided into two major groups: (a) idiopathic long QT syndrome (LQTS), which include the Jervell-Lange-Nielsen and the Romano-Ward syndromes; and (b) acquired prolonged QT syndromes, which are largely iatrogenic and may follow treatment with antiarrhythmic drugs, tricyclic antidepressants, phenothiazines or macrolide antibiotics, and may be associated with metabolic disturbances (hypokalaemia, hypocalcaemia and hypomagnesaemia).
Clinical studies have provided criteria for the definition and guidelines for the management of torsade de pointes, while the electrophysiological mechanisms responsible for its onset are still unclear. Two pathogenetic hypotheses have been proposed to account for the electrophysiological mechanisms underlying the condition: (a) re-entry due to a dispersion of refractory periods; and (b) triggered activity initiated by either early or delayed after-depolarisations. Both mechanisms are supported by clinical and experimental observations but a conclusive answer is not yet available.
Similar content being viewed by others
References
Bailie DS, Inoue H, Kaseda S, Ben-David J, Zipes DP. Magnesium suppression of early after depolarizations and ventricular arrhythmias induced by caesium in dogs. Circulation 77: 1395–1402, 1988
Bhandari AK, Scheimann M. The long QT syndrome. Modern Concepts in Cardiovascular Disease 54: 45, 1985
Bhandari AK, Shapiro WA, Morady F, Shen EN, Mason J, et al. Electrophysiologic testing in patients with the long QT syndrome. Circulation 71: 63–71, 1985
Bonatti V, Rolli A, Botti G. Recording of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias. European Heart Journal 4: 168–179, 1983
Brachman J, Scherlag BJ, Rosenshtraukh LV, Lazzara R. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 68: 846–856, 1983
Chow MJ, Piergies AA, Bowsher DJ, Murphy JJ, Kushner W, et al. Torsades de Pointes induced by N-acetylprocainamide. Journal of the American College of Cardiology 4: 621–624, 1984
Curry P, Fitchett D, Stubbes W, Kirkler D. Ventricular arrhythmias and hypokalemia. Lancet 2: 231–233, 1976
Day CP, McComb JM, Campbell RWF. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. British Heart Journal 63: 342–344, 1990
Day CP, McComb JM, Matthews J, Campbell RWF. Reduction in QT dispersion by sotalol following myocardial infarction. European Heart Journal 12: 423–427, 1991
Dessertenne F. Un chapitre nouveau d’electrocardiographie: les variations progressives de l’amplitude de l’electrocardiogramme. Actualites Cardiologiques et Angiologique Internationale 15: 241–258, 1966a
Dessertenne F. La tachycardia ventriculaire a deux foyers opposes variable. Archives des Maladies du Coeur et des Vaisseaux 59: 263–272, 1966b
Fowler NO, McCall D, Chou T, Holmes JC, Hanenson IB. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. American Journal of Cardiology 37: 223–230, 1976
Franz MR. Long term recording of monophasic action potential from human endocardium. American Journal of Cardiology 51: 1629–1635, 1983
Franz MR, Burkhoff D, Spurgeon H, Wiesfeldt ML, Lakatta EG. In vitro validation of a new catheter technique for recording monophasic action potentials. European Heart Journal 7: 34–41, 1986
Gavrilescu S, Luca C. Right ventricular monophasic action potentials in patients with long QT syndrome. British Heart Journal 40: 1014–1018, 1978
Guelon D, Bedock B, Chartier C, Haberer JP. QT prolongation and recurrent ‘Torsades de Pointes’ during erythromycin lactobionate infusion. American Journal of Cardiology 59: 168–169, 1987
Habbab MA, El-Sherif N. Drug-induced Torsades de Pointes: role of early afterdepolarizations and dispersion of repolarization. American Journal of Medicine 89: 241–246, 1990
Han J, Moe JK. Non uniform recovery of excitability in ventricular muscle. Circulation Research 14: 44–60, 1964
Hii JTY, Wyse GD, Gillis AM, Duff HJ, Solyloo MA, et al. Precordial QT interval dispersion as a marker of Torsades de Pointes. Circulation 86: 1376–1382, 1992
Inser JM, Sours HE, Paris AL, Ferrans VJ, Roberts WC. Sudden, unexpected death in avid dieters using the liquid-protein-modifiedfast diet. Observations in 17 patients and the role of prolonged QT interval. Circulation 6: 1401–1412, 1979
Jackman WM, Friday KJ, Anderson JL Aliot EA, Clark M, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Progress in Cardiovascular Diseases 31: 115–172, 1988
Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death. American Heart Journal 54: 59–68, 1957
Kahn MN, Logan KR, McComb JM, Adgey JAA. Management of recurrent ventricular tachyarrhythmias associated with QT prolongation. American Journal of Cardiology 47: 1301–1308, 1981
Kay GN, Plumb VJ, Arciniegas JG, Henthorn RW, Waldo AL. Torsades de Pointes: the long-short initiating sequence and other clinical features. American Journal of Cardiology 2: 806–817, 1983
Keren A, Tzivoni D, Gavish D, Levi J, Gottlieb S, et al. Etiology, warning, signs and therapy of Torsades de Pointes. A study of 10 patients. Circulation 64: 1167–1174, 1981
Kuchar DDL, Thorburn CW, Sammel NL. Late potentials detected after myocardial infarction: natural history and pathogenetic significance. Circulation 74: 1280–1289, 1986
Kuck Kh, Kunze KP, Roewer N. Sotalol induced Torsades de Pointes. American Heart Journal 107: 179–180, 1984
Kuo CS, Munakata K, Reddy CP, Surawicz B. Characteristics and possible mechanism of ventricular arrhythmia dependent on dispersion of action potential duration. Circulation 67: 1356–1367, 1983
Lansman JB, Hess P, Tsien RW. Blockade of current through the single calcium channels by Cd++, Mg++, Ca++. Journal of General Physiology 88: 321–347, 1987
Malfatto G, Rosen MR, Foresti A, Schwartz PJ. Idiopathic long QT syndrome exacerbated by beta adrenergic blockade and responsive to left cardiac sympathetic denervation: implications regarding electrophysiologic substrate and adrenergic modulation. Journal of Cardiovascular Electrophysiology 13: 1304–1310, 1992
Maloney JD, Nissen RG, McColgan BS. Open clinical studies at a referral centre. Chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents. American Heart Journal 100: 1023–1030, 1980
Maor N, Weiss D, Lorber A. Torsades de Pointes complicating AV block: report of two cases. International Journal Cardiology 14: 235, 1987
Mason JW, Hondeghen LM, Katzung BG. Block of inactivated sodium channels depolarization induced automaticity in guinea pig papillary muscle by amiodarone. Circulation Research 55: 277–285, 1984
McComb JM, Campbell NPS, Clelend J. Recurrent ventricular tachycardia with QT prolongation after initial valve replacement and its association with intravenous administration of erythromycin. American Journal of Cardiology 54: 922–923, 1984
Moore MT, Book MH. Sudden death in phenothiazine therapy. A clinicopathologic study of 12 cases. Psychiatric Quarterly 44: 384–402, 1970
Moss AJ, Liu JE, Gotlieb S, Locati EH, Robinson L, et al. Efficacy of permanent pacing in the management of the long QT syndrome. Circulation 82 (Suppl. III): 181, 1990
Moss AJ, Schwartz PJ, Crampton RS, Locati EH, Carleen E, et al. The long QT syndrome: a prospective international study. Circulation 71: 17–21, 1985
Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati E, et al. The long QT syndrome prospective longitudinal study of 328 families. Circulation 84: 1136–1144, 1991
Motoe K, Saku K, Tashiro N, Hiroki T, Arahva K. Torsades de Pointes and atrioventricular block. Clinical Cardiology 11: 9–13, 1988
Napolitano C, Bonazzi O, Diehl L, Locati EH, Priori SG, et al. Dispersion of ventricular activation in the long QT syndrome. Circulation 86 (Suppl. I): 391, 1992
Nattel S, Ranger S, Talajic M, Lemery R, Roy D. Erythromycin-induced long QT syndrome: concordance with Quinidine and underlying cellular electrophysiologic mechanism. American Journal of Medicine 89: 235–238, 1990
Nguyen PT, Sheimann M, Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy and QT interval. Circulation 74: 340, 1986
Nishamura M, Follner CH, Singer DA. Amiodarone blocks calcium current in single guinea pig ventricular myocytes. Journal of Pharmacology and Experimental Therapeutics 251: 650–659, 1989
Priori SG, Corr PB. Mechanism underlying early and delayed after depolarizations induced by catecholamine in isolated canine ventricular myocytes. American Journal of Physiology 258: H1796–H1805, 1990
Priori SG, Mantica M, Schwartz PJ. Delayed after depolarizations elicited in vivo by left stellate ganglion stimulation. Circulation 78: 178–185, 1988
Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of repolarization as a marker to predict efficacy of antiadrenergic therapy. Journal of the American College of Cardiology 21: 94A, 1993
Ricioni N, Castiglioni M, Bartolomei C. Dysopiramide-induced QT prolongation and ventricular tachyarrhythmias. American Heart Journal 105: 870–871, 1983
Roden DM, Thompson KA, Hoffman BF, Woosley RL. Clinical features and basic mechanisms of Quinidine-induced arrhythmias. Journal of the American College of Cardiology 8: 73A, 1986
Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the Quinidine associated long QT syndrome: implications for patient care. American Heart Journal 111: 1088–1094, 1986
Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare in eta’ pedriatica. Clinical Pediatrics 45: 656–683, 1963
Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanism in a canine model of erythromycin-associated long QT syndrome. Circulation 88: 1832–1844, 1993
Schoonmaker FW, Osten RT, Greenfiled JC Jr. Thioridazine (‘Meilern’) induced ventricular tachycardia controlled with an artificial pacemaker. Annals of Internal Medicine 65: 1076–1078, 1966
Schwartz PJ. The idiopathic long QT syndrome: progress and questions. American Heart Journal 109: 399–411, 1985
Schwartz PJ, Locati E. The idiopathic long QT syndrome: pathogenetic mechanisms and therapy. European Heart Journal 6 (Suppl. D): 103–114, 1985
Schwartz PJ, Bonazzi O, Locati EH, Napolitano C, Sala S. Pathogenesis and therapy of the long QT syndrome. In Hashiba et al. (Eds) QT Prolongation and ventricular arrhythmias. Annals of the New York Academy of Sciences 644: 112–141, 1992
Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, et al. Left cardiac sympathetic denervation in the therapy of the congenital long QT syndrome: a worldwide report. Circulation 84: 503–511, 1991
Sclarovsky S, Strasberg B, Lewin RF, Agmon J. Polymorphous ventricular tachycardia: clinical features and treatment. American Journal of Cardiology 44: 339–344, 1979
Shah A, Schwartz H. Mexiletine for treatment of Torsades de Pointes American Heart Journal 107: 589–591, 1984
Shimizu W, Ohe T, Kurita T, Takaki H, Aihara N, et al. Early after depolarizations induced by isoproterenol in patients with congenital long QT syndrome. Circulation 84: 1915–1923, 1991
Simpson GG, Roe A, Lewontin RC. Quantitative zoology, p. 440, Harcourt, Brace & Jovanovich, New York, 1969
Stern S, Keren A, Tzivoni D. Torsades de pointes: definition, causative factors and therapy. Experience with sixteen patients. Annals of the New York Academy of Sciences 427: 234–240, 1984
Stramba-Badiale M, Guffanti S, Porta N, Frediani M, Beria G, et al. QT interval prolongation and cardiac arrest during therapy with spiramycin in a new-born infant. American Heart Journal 126: 740–742, 1993
Strasberg B, Sclarovsky S, Erdberg A, Duffy EC, Lam W, et al. Procainamide-induced Polymorphous ventricular tachycardia. American Journal of Cardiology 47: 1309–1314, 1981
Surawicz B. Electrophysiologic substrate of Torsades de Pointes: dispersion of repolarization or early after depolarizations?. Journal of the American College of Cardiology 14: 172–84, 1989
Tzivoni D, Keren A, Cohen AM, Loebel H, Zahavi I, et al. Magnesium therapy of Torsades de Pointes. American Journal of Cardiology 53: 528–530, 1984
Tzivoni D, Keren A, Stern S, Gotlieb S. Disopyramide-induced Torsades de Pointes. Archives of Internal Medicine 141: 946–947, 1981
Ward OC. New familial cardiac syndrome in children. Journal of the Irish Medical Association 54: 103–106, 1964
Wit AL, Rosen MR. After depolarizations and triggered activity. In Fozzard (Ed.) The heart and the cardiovascular system, pp. 1449–1489, Raven Press, New York, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Napolitano, C., Priori, S.G. & Schwartz, P.J. Torsade de Pointes. Drugs 47, 51–65 (1994). https://doi.org/10.2165/00003495-199447010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199447010-00004